Gilead Increasingly Seems Focused On Combo Therapy In NASH
Executive Summary
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.
You may also be interested in...
Gilead’s Bad Luck In NASH Continues With ATLAS Failure
None of the two-drug combinations tested by Gilead met statistical significance in the multi-arm non-alcoholic steatohepatitis trial. This follows the Phase III failure of selonsertib monotherapy earlier in 2019.
NASH Companies Take The Stage At AASLD
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future
Gilead detailed its Phase III failure with ASK1 inhibitor selonsertib in NASH, but anticipates finding a new regimen to take into Phase III in NASH with the ATLAS combination study data expected in December.
Need a specific report? 1000+ reports available
Buy Reports
